Our paper shines light into the role of other brain areas outside of the cerebellum that are affected in SCA1. In particular, we found that a mouse model of SCA1 likely passes away from declining respiratory functions, which correlates with motor neuron degeneration.
"More opportunities to showcase early investigators' work early in solid journals is valuable as it can set the basis for further studies and provides some momentum to expand the project and obtain funding."
What are the main advantages and drawbacks of the model system you have used as it relates to the disease you are investigating?
We use a knock-in mouse model to study SCA1. The major advantage of this model is that expression of the pathogenic SCA1 protein occurs at physiological levels in a natural temporal and spatial pattern. When studying neurodegenerative diseases, which take decades of expression of pathogenic proteins to have an effect on cell death, using a short lifespan organism (mouse) as a model can be a drawback in demonstrating the full extent of disease.
What has surprised you the most while conducting your research?
The resilience of mice to overcome and/or adapt to a toxic perturbation in humans is very intriguing me.
Describe what you think is the most significant challenge impacting your research at this time and how will this be addressed over the next 10 years?
The greatest hurdle to my research program at present is being able to study molecular events in vivo and in isolation within motor neurons. Exciting improvements in technology such as the development of high-resolution light microscopy from investigators such as Ed Boyden at MIT will greatly improve access.
What changes do you think could improve the professional lives of early-career scientists?
More opportunities to showcase early investigators' work early in solid journals is valuable as it can set the basis for further studies and provides some momentum to expand the project and obtain funding.
What's next for you?
I am currently developing a novel mouse model for spinocerebellar ataxia type 1 that will allow me to study cell-specific effects from expression of the mutant disease protein.
